Sanjay K. Kakkar
Directeur Général chez Tranquis Therapeutics, Inc.
Profil
Sanjay K.
Kakkar currently works at Tranquis Therapeutics, Inc., as President & Chief Executive Officer from 2018.
Dr. Kakkar also formerly worked at Trigen Holdings AG, as Chief Executive Officer from 1997 to 2009, Armetheon, Inc., as Chief Executive Officer, Peptilogics, Inc., as Chief Executive Officer & Director, Novartis Corp., as Product Manager, and Pharmacia, Inc., as Principal.
Dr. Kakkar received his graduate degree from Harvard University, graduate degree from Imperial College London, and doctorate degree from King's College London.
Postes actifs de Sanjay K. Kakkar
Sociétés | Poste | Début |
---|---|---|
Tranquis Therapeutics, Inc.
Tranquis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA. | Directeur Général | 01/01/2018 |
Anciens postes connus de Sanjay K. Kakkar
Sociétés | Poste | Fin |
---|---|---|
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | President | 15/12/2009 |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | Directeur Général | - |
Armetheon, Inc.
Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Directeur Général | - |
Pharmacia, Inc. | Corporate Officer/Principal | - |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Sanjay K. Kakkar
Harvard University | Graduate Degree |
King's College London | Doctorate Degree |
Imperial College London | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 6 |
---|---|
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | Commercial Services |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Pharmacia, Inc. | |
Armetheon, Inc.
Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Health Technology |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | Commercial Services |
Tranquis Therapeutics, Inc.
Tranquis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA. | Health Technology |